At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed glioblastoma multiforme that has progressed, recurred, or persisted after initial standard therapy (radiotherapy and/or chemotherapy)
- ✓Measurable disease by MRI or CT scan
- ✓Tumor at least 5 mm in size
- ✓Age 18 years or older
- ✕Brain stem tumor
- ✕Uncontrolled hypertension or history of congestive heart failure
- ✕Serious lung disease such as severe COPD
- ✕Prior antineoplaston therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients With Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating Antineoplaston therapy (Atengenal + Astugenal) for Glioblastoma Multiforme of the Brain. Completed, enrolled 40 participants across 1 site.
Detailed Summary
RATIONALE: Current therapies for Glioblastoma Multiforme provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of brain tumors. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults (≥ 18 years of age) with residual/recurrent/progressive Glioblastoma Multiforme.
Study Details
Timeline
Interventions
Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.